VKTX Earnings Prediction
The chart below shows how VKTX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VKTX sees a +0.70% change in stock price 10 days leading up to the earnings, and a +7.47% change 10 days following the report. On the earnings day itself, the stock moves by -0.90%. This data can give you a slight idea of what to expect for the next quarter's release.
VKTX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
0.00
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.22
-4.35%
10.00%
No Data Available
VKTX Earnings Analysis
Viking Therapeutics, Inc Corporation (VKTX.O) Earnings Conference Call
Positive
Clinical Program Advancements: The company delivered positive data from four clinical programs, showcasing promising in vivo data from a new preclinical program.
Obesity Treatment Efficacy: The Phase 2 VENTURE trial evaluating subcutaneous VK2735 for the treatment of obesity demonstrated impressive reductions in body weight after 13 weeks of treatment.
VK2809 Trial Results: Initial results from a 28-day Phase 1 trial evaluating a novel oral formulation of VK2809 showed excellent tolerability and encouraging reductions in body weight.
Positive Phase 2b Results: During the second quarter, the company announced positive histology results from the Phase 2b VOYAGE study evaluating VK2809 for the treatment of NASH and fibrosis, showing reductions in liver fat at 12 weeks.
Net Loss Increase: The company reported a net loss of $24.9 million for the three months ended September 30, 2024, which was an increase from a net loss of $22.5 million in the corresponding period in 2023, primarily due to increased research and development expenses.
Negative
R&D Expense Increase: Research and development expenses were $22.8 million for the three months ended September 30, 2024, compared to $18.4 million for the same period in 2023, indicating a significant increase in costs.
Rising Administrative Expenses: General and administrative expenses were $13.8 million for the three months ended September 30, 2024, compared to $8.9 million for the same period in 2023, reflecting a substantial rise in operational costs.
Net Loss Comparison: Viking reported a net loss of $24.9 million or $0.22 per share compared to a net loss of $22.5 million or $0.23 per share in the corresponding period in 2023, showing a worsening financial position.
Net Loss Comparison: For the nine months ended September 30, 2024, Viking reported a net loss of $74.5 million or $0.69 per share compared to a net loss of $61.3 million or $0.66 per share in the corresponding period in 2023, indicating a decline in financial performance.
Net Loss Increase Factors: The increase in net loss for the nine months ended September 30, 2024, was primarily due to the increase in research and development expenses and general and administrative expenses, which were not offset by increased interest income.
VKTX FAQs
How does VKTX typically perform around its earnings report dates?
Is Viking Therapeutics, Inc. (VKTX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VKTX Earning Call Sentiment
Viking Therapeutics, Inc. (VKTX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
VKTX.O
-1.77%Positive
Basic Financial Performance: 3. Financials show increased R&D and G&A expenses, but a strong cash position. Product Development and Business Update: 4. Progress in clinical trials and new formulations, but some supply chain concerns. Market Strategy: 3. Expansion in trials, but no new partnerships. Expenses and Financial Health: 3. Rising expenses and net loss, but offset by increased cash. Shareholder Return Plan: 2. No buybacks or dividends announced. The Q&A section highlighted management's cautious approach, leading to a neutral sentiment. Overall, the positive trial developments are balanced by financial concerns, resulting in a neutral stock price prediction.
